Agios Pharmaceuticals, Inc.: U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease

FDA's PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIR ...
Goldseiten

Rare Earths Americas Identifies Large Rare Earth-Niobium Alkaline-Carbonatite System; Discovery Model Strengthens as 15,000m Drill Program Gets Underway at Homer

Rare Earths Americas, Inc. , today announced exploration results that strengthen the Company's geological discovery model at its 100%-owned Homer-A project in Brazil's Goiás Alkaline Province .

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

FDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell ...